CSMS Physicians Leading CT Medical Marijuana Research Efforts

New medical research projects are placing Connecticut at the forefront of national medical marijuana research. Earlier today, the Connecticut Hospice hosted a press conference to highlight its newly-approved medical marijuana research project. CSMS member and AMA Delegate Ted Zanker, MD is the principal investigator for the research project, which is designed to reduce opioid use […]

Read More +

LCMA 250th Anniversary Celebration

The Litchfield County Medical Association is now in its 250th year, making it among the oldest (if not the oldest) continuously operating medical association in the country. The LCMA celebrated this milestone at Weatherstone, an historic property in Sharon, CT built by Simeon Smith, MD in 1765. Historical records indicate that Dr. Smith hosted meetings […]

Read More +

National Attention for CT Opioid Efforts

Earlier today, CSMS was honored to host a special meeting on opioid prescribing and addiction issues with Michael Botticelli, Director of the White House White House Office of National Drug Control Policy, and a multidisciplinary group of practicing Connecticut physicians. Director Botticelli was joined by US Representative Rosa DeLauro (CT-03) for an opportunity to hear directly […]

Read More +

Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) 12/10/14

This event is now at capacity and registration has been closed – 11/25/13. The next scheduled opioid prescribing CME event is the SCOPE of Pain program on March 13, 2015. Click here for details. The ER/LA Opioid Anaglesics REMS program will cover four distinct areas: • Assess patients for the treatment of pain with ER/LA […]

Read More +

Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) 11/10/14

The ER/LA Opioid Anaglesics REMS program will cover four distinct areas: • Assess patients for the treatment of pain with ER/LA opioid analgesics, including analyzing risks versus potential benefits, including psychiatric history and risk of substance use. • Incorporate strategies to effectively initiate and manage therapy, modify dosing or discontinue use of ER/LA opioid analgesics […]

Read More +

Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) 11/8/14

The ER/LA Opioid Anaglesics REMS program will cover four distinct areas: • Assess patients for the treatment of pain with ER/LA opioid analgesics, including analyzing risks versus potential benefits, including psychiatric history and risk of substance use. • Incorporate strategies to effectively initiate and manage therapy, modify dosing or discontinue use of ER/LA opioid analgesics […]

Read More +

Extended-Release and Long-Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) 11/7/14

The ER/LA Opioid Anaglesics REMS program will cover four distinct areas: • Assess patients for the treatment of pain with ER/LA opioid analgesics, including analyzing risks versus potential benefits, including psychiatric history and risk of substance use. • Incorporate strategies to effectively initiate and manage therapy, modify dosing or discontinue use of ER/LA opioid analgesics […]

Read More +

Login

Lost your password?
MENU